Mucinex Childrens Mighty Chews Cold and Flu

Description

Children's Mucinex® is a cough suppressant formulated for pediatric use in children aged 6 years and older. Each chewable tablet contains 5 mg of dextromethorphan hydrobromide (HBr) as the active ingredient. The product is presented in a mixed berry flavor, designed to enhance palatability for younger patients. The National Drug Code (NDC) for this formulation is 72854-084-016.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritation, which may occur due to a cold.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 2 chewable tablets every 4 hours, with a maximum limit of 12 chewable tablets within a 24-hour period. For children aged 6 to under 12 years, the dosage is 1 chewable tablet every 4 hours, not to exceed 6 chewable tablets in a 24-hour period.

It is essential that the tablets are chewed thoroughly before swallowing to ensure proper absorption.

For children under 6 years of age, the use of this medication is not recommended. Healthcare professionals should advise patients to follow these guidelines or any specific instructions provided by their physician.

Contraindications

Use is contraindicated in individuals who are pregnant or breastfeeding; consultation with a healthcare professional is advised prior to use in these populations.

Additionally, the product should be kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought or contact with a Poison Control Center is recommended.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, it should not be used for a period of two weeks following the cessation of an MAOI. Healthcare professionals should advise patients to consult with a doctor or pharmacist if there is uncertainty regarding the presence of an MAOI in their prescription medications.

General precautions should be taken prior to use. Patients are advised to seek medical advice if they have a sodium-restricted diet, a persistent or chronic cough associated with smoking, asthma, or emphysema, or if they experience a cough accompanied by excessive phlegm (mucus).

During the use of this product, it is imperative that patients do not exceed the recommended dosage.

Patients should be instructed to discontinue use and contact their healthcare provider if their cough persists for more than seven days, recurs, or is accompanied by fever, rash, or headache, as these symptoms may indicate a serious underlying condition.

In the event of an overdose, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients should be aware of the potential adverse reactions associated with this product. Serious adverse reactions may occur, particularly in individuals who are currently taking or have recently discontinued a prescription monoamine oxidase inhibitor (MAOI). The use of this product is contraindicated in such cases, as it may lead to significant health risks.

Common adverse reactions may include symptoms related to the respiratory system. Patients with a sodium-restricted diet, persistent or chronic cough (such as that associated with smoking, asthma, or emphysema), or cough accompanied by excessive phlegm should consult a healthcare professional before using this product.

While using this product, it is crucial for patients to adhere to the recommended dosage. Exceeding this dosage may increase the risk of adverse effects. Patients are advised to discontinue use and seek medical advice if their cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or headache, as these symptoms could indicate a serious underlying condition.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric conditions, or Parkinson’s disease. Patients should not take this product while on MAOIs or for a minimum of two weeks following the discontinuation of an MAOI.

It is essential for patients to consult with a healthcare professional, such as a doctor or pharmacist, to verify whether their current prescription includes an MAOI before initiating treatment with this product.

Packaging & NDC

Below are the non-prescription pack sizes of Mucinex Childrens Mighty Chews Cold and Flu (acetaminophen and dextromethorphan hydrobromide). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should not use this medication. For children aged 6 to under 12 years, the recommended dosage is 1 chewable tablet every 4 hours, with a maximum of 6 chewable tablets in a 24-hour period. In contrast, adults and children 12 years of age and older may take 2 chewable tablets every 4 hours, not exceeding 12 chewable tablets in any 24-hour period. Care should be taken to adhere to these dosing guidelines to ensure safety and efficacy in pediatric use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

Exceeding the recommended dosage of this product may lead to serious health consequences. Healthcare professionals are advised to monitor patients closely for any signs of overdosage and to educate patients on the importance of adhering to the prescribed dosage guidelines.

In the event of suspected overdosage, it is crucial to assess the patient for potential symptoms, which may vary depending on the specific product and individual patient factors. Common symptoms associated with overdosage may include, but are not limited to, gastrointestinal disturbances, neurological effects, and cardiovascular complications.

Management of overdosage should be initiated promptly. Healthcare providers should consider supportive care measures, including the stabilization of vital signs and symptomatic treatment. In cases where the overdosage is significant, further interventions such as activated charcoal administration or other decontamination methods may be warranted, depending on the time elapsed since ingestion and the clinical scenario.

It is essential for healthcare professionals to consult the product's prescribing information for specific recommendations regarding the management of overdosage, including any antidotes or specific treatment protocols that may be applicable.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: nausea, vomiting, constipation, dizziness, and drowsiness. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Healthcare providers should advise patients to consult a health professional if they are pregnant or breastfeeding before using this medication. It is important for patients to understand the potential risks and benefits associated with its use during these periods.

Providers should also emphasize the importance of keeping the medication out of reach of children. In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance. This information is crucial for ensuring patient safety and preventing adverse outcomes.

Storage and Handling

The product is supplied in a package configuration that includes specific NDC numbers. It should be stored in a cool, dry place, maintaining a temperature range of 20-25°C (68-77°F). Proper storage conditions are essential to ensure the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Mucinex Childrens Mighty Chews Cold and Flu, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)